Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $1.91 (11%) to $19.40 Independence Day week after the European Commission approved Iclusig ponatinib to treat chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) was down $0.05 to $2.45 last week after it resubmitted an NDA to FDA for Northera droxidopa to treat symptomatic neurogenic orthostatic hypotension (NOH). The company said it expects a PDUFA date in 1Q14.
Omthera Pharmaceuticals Inc. (NASDAQ:OMTH) was down $0.17 to $13.25 last week after submitting an NDA to FDA for Epanova to treat severe hypertriglyceridemia. Omthera is being acquired by AstraZeneca plc (LSE:AZN; NYSE:AZN).
Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) was up $0.41 to $15.59 on July 5 after Germany's Federal Joint Committee (G-BA) issued a final benefit assessment concluding Dificlir fidaxomicin has "significant" additional benefit over vancomycin to treat severe or recurrent Clostridium difficile-associated diarrhea (CDAD).
Optimer finished Independence Day week up $1.12.
Orexo AB (SSE:ORX) rose SEK8 (12%) to SEK74 on July 4 after FDA approved an NDA for Zubsolv buprenorphine/naloxone for maintenance treatment of opioid dependence. Earlier in the week, Orexo announced a partnership with Publicis Touchpoint Solutions to commercialize Zubsolv in the U.S.
Orexo finished the week up SEK13.50 (23%) to SEK71.50 for Independence Day week.
Pharmacyclics Inc. (NASDAQ:PCYC) gained $10.74 (21%) to $100.26 on Wednesday after announcing it submitted an NDA